Madrigal Pharmaceuticals (MDGL) Cash from Financing Activities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Cash from Financing Activities for 17 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 78.75% year-over-year to $3.1 million; the TTM figure through Jun 2026 stood at $251.0 million (up 567.42% YoY), while the FY2025 annual figure was $256.0 million, down 65.18% from the prior year.
• Cash from Financing Activities grew to $3.1 million in Q2 2026 per MDGL's latest filing, from $2.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $573.7 million in Q1 2024 and bottomed at $1.7 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged $119.1 million across 5 years, with a median of $31.4 million in 2023.
• On a YoY basis, Cash from Financing Activities climbed as much as 3071.36% in 2025 and fell as far as 98.7% in 2025.
• Madrigal Pharmaceuticals' Cash from Financing Activities stood at $264.3 million in 2022, then jumped by 81.55% to $479.9 million in 2023, then slumped by 95.88% to $19.8 million in 2024, then tumbled by 54.7% to $9.0 million in 2025, then slumped by 65.25% to $3.1 million in 2026.
• Business Quant data shows MDGL's Cash from Financing Activities at $3.1 million in Q2 2026, $2.3 million in Q1 2026, and $9.0 million in Q4 2025.